ArticleScientific reports2025
The value of prealbumin in predicting post hepatectomy liver failure for patients with hepatocellular carcinoma undergoing major hepatectomy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a personalized web-based calculator of aggressive recurrence after surgery for early-stage hepatocellular carcinoma by machine learning.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Post hepatectomy liver failure (PHLF) poses a significant threat to the prognosis of patients with hepatocellular carcinoma (HCC), particularly those undergoing major hepatectomy. The present research endeavors to clarify the influence of prealbumin on the development of PHLF in HCC patients who have undergone major hepatectomy. Patients with HCC who have undergone major hepatectomy were included. Based on the ROC curve, the optimal cut-off value for prealbumin was determined and patients were divided into two groups. Univariate and multivariate logistic analyses were conducted to identify risk factors for PHLF in HCC patients. Furthermore, the predictive ability of PHLF was also evaluated. 466 patients were included, among whom 98 (21%) developed PHLF. Compared with the high prealbumin group, patients in the low prealbumin group had significantly higher proportions of cirrhosis, portal hypertension, intraoperative blood loss, and transfusion, as well as a higher incidence of PHLF (12.3% vs. 23.5%, P = 0.011). Multivariate analysis revealed that prealbumin is a risk factor for PHLF (HR 1.446, 95%CI 1.091-2.369, P = 0.015), but it is not a risk factor for severe PHLF (HR 1.183, 95%CI 0.584-2.692, P = 0.289). However, the comprehensive indicator, prealbumin-bilirubin (preALBI), is not only a risk factor for PHLF but also severe PHLF. Furthermore, its predictive performance is significantly higher than that of other related indicators (all P < 0.05). Patients with low prealbumin levels require perioperative protocols: precise resection control, liver volume assessment, and PHLF prevention monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.